tetano
Editor, Senior Moderator
Nat Commun
. 2022 Jun 9;13(1):3203.
doi: 10.1038/s41467-022-30884-6.
Waning effectiveness of the third dose of the BNT162b2 mRNA COVID-19 vaccine
Tal Patalon[SUP] 1 2 [/SUP], Yaki Saciuk[SUP] 3 [/SUP], Asaf Peretz[SUP] 4 5 [/SUP], Galit Perez[SUP] 4 [/SUP], Yoav Lurie[SUP] 6 [/SUP], Yasmin Maor[SUP] 7 8 [/SUP], Sivan Gazit[SUP] 3 4 [/SUP]
Affiliations
Abstract
The duration of protection of the third (booster) dose of the BioNTech/Pfizer BNT162b2 mRNA Coronavirus Disease 2019 vaccine has been the subject of recent investigations, as global discussions around the necessity and effectiveness of a fourth dose are already underway. By conducting a retrospective study implementing a test-negative case-control design, analyzing 546,924 PCR tests performed throughout January 2022 by 389,265 persons who received at least two doses, we find that the effectiveness in each month-since-vaccination decreases significantly. Compared to those vaccinated five months prior to the outcome period, on August 2021, relative protection against infection waned from 53.4% a month after vaccination to 16.5% three months after vaccination. These results suggest that there is a significant waning of vaccine effectiveness against the Omicron variant of the third dose of the BNT162b2 vaccine within a few months after administration. Additional information could assist to comprehensively estimate the effectiveness of the three-dose-strategy.
. 2022 Jun 9;13(1):3203.
doi: 10.1038/s41467-022-30884-6.
Waning effectiveness of the third dose of the BNT162b2 mRNA COVID-19 vaccine
Tal Patalon[SUP] 1 2 [/SUP], Yaki Saciuk[SUP] 3 [/SUP], Asaf Peretz[SUP] 4 5 [/SUP], Galit Perez[SUP] 4 [/SUP], Yoav Lurie[SUP] 6 [/SUP], Yasmin Maor[SUP] 7 8 [/SUP], Sivan Gazit[SUP] 3 4 [/SUP]
Affiliations
- PMID: 35680872
- DOI: 10.1038/s41467-022-30884-6
Abstract
The duration of protection of the third (booster) dose of the BioNTech/Pfizer BNT162b2 mRNA Coronavirus Disease 2019 vaccine has been the subject of recent investigations, as global discussions around the necessity and effectiveness of a fourth dose are already underway. By conducting a retrospective study implementing a test-negative case-control design, analyzing 546,924 PCR tests performed throughout January 2022 by 389,265 persons who received at least two doses, we find that the effectiveness in each month-since-vaccination decreases significantly. Compared to those vaccinated five months prior to the outcome period, on August 2021, relative protection against infection waned from 53.4% a month after vaccination to 16.5% three months after vaccination. These results suggest that there is a significant waning of vaccine effectiveness against the Omicron variant of the third dose of the BNT162b2 vaccine within a few months after administration. Additional information could assist to comprehensively estimate the effectiveness of the three-dose-strategy.